Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study

被引:74
作者
Duffner, PK
Krischer, JP
Horowitz, ME
Cohen, ME
Burger, PC
Friedman, HS
Kun, LE
机构
[1] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Johns Hopkins Sch Med, Baltimore, MD USA
[5] Duke Univ, Med Ctr, Durham, NC USA
[6] St Jude Childrens Res Hosp, Memphis, TN USA
关键词
D O I
10.1002/ana.410440305
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Between 1986 and 1990, the Pediatric Oncology Group conducted a study in which 198 children younger than 3 years of age with malignant brain tumors were treated with prolonged postoperative chemotherapy in an effort to delay irradiation and reduce long-term neurotoxicity. Children younger than 2 years of age received 24 months of chemotherapy followed by irradiation, and those between 2 and 3 years of age received 12 months of chemotherapy plus irradiation. Chemotherapy was given in 28-day cycles (AAB, AAB), with cycle A = vincristine (0.065 mg/kg) intravenously on days 1 and 8 and cyclophosphamide (65 mg/kg) intravenously on day 1, and cycle B = cisplatinum (4 mg/kg) intravenously on day 1 and etoposide (6.5 mg/kg) intravenously on days 3 and 4. Five of the 198 children developed second malignancies, with a cumulative risk at 8 years of 11.3% (95% confidence interval [CI], 0-39%). Four of the five second malignancies occurred in children younger than 2 years of age at diagnosis, with a cumulative risk at 8 years of 18.9% (CI, 0-70%). Initial diagnoses were choroid plexus carcinoma (2 children), ependymoma (1 child), desmoplastic infantile ganglioglioma (2 children), and medulloblastoma (1 child). Duration from diagnosis of initial tumor to second malignancy was 33, 35, 57, 66, and 92 months. Three children younger than 2 years of age developed lymphoproliferative disease, that is, myelodysplastic syndrome (2 children), both with monosomy 7 deletions, and acute myelogenous leukemia (1 child), after 24 to 26 cycles of chemotherapy, including 8 cycles of etoposide. Two of 3 received craniospinal irradiation (2,560/3,840 cGy) and (3,520/5,320 cGy). Time to second malignancy was 7 years 8 months, 4 years 9 months, and 2 years 9 months. Two children developed solid tumors, at 5 years 6 months and 2 years 11 months, respectively, after initiation of treatment. A sarcoma developed after 26 cycles of chemotherapy and no irradiation, and a meningioma developed after 12 cycles of chemotherapy and local craniospinal irradiation. Potential causative factors for this high rate of secondary malignancies include prolonged use of alkylating agents and etoposide with or without irradiation.
引用
收藏
页码:313 / 316
页数:4
相关论文
共 23 条
  • [1] FATAL LONG-TERM SEQUELA FOLLOWING RADIATION CURE FOR EPENDYMOMA
    BACHMAN, DS
    OSTROW, PT
    [J]. ANNALS OF NEUROLOGY, 1978, 4 (04) : 319 - 321
  • [2] BOGDANOWICZ WM, 1974, SURG NEUROL, V2, P379
  • [3] CANTOR A, 1997, EXTENDING SAS SURVIV, P27
  • [4] POSTOPERATIVE CHEMOTHERAPY AND DELAYED RADIATION IN CHILDREN LESS-THAN 3 YEARS OF AGE WITH MALIGNANT BRAIN-TUMORS
    DUFFNER, PK
    HOROWITZ, ME
    KRISCHER, JP
    FRIEDMAN, HS
    BURGER, PC
    COHEN, ME
    SANFORD, RA
    MULHERN, RK
    JAMES, HE
    FREEMAN, CR
    SEIDEL, FG
    KUN, LE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24) : 1725 - 1731
  • [5] POSTOPERATIVE CHEMOTHERAPY AND DELAYED RADIATION IN INFANTS AND VERY YOUNG-CHILDREN WITH CHOROID-PLEXUS CARCINOMAS
    DUFFNER, PK
    KUN, LE
    BURGER, PC
    HOROWITZ, ME
    COHEN, ME
    SANFORD, RA
    KRISCHER, JP
    MULHERN, RK
    JAMES, HE
    REKATE, HL
    FRIEDMAN, HS
    [J]. PEDIATRIC NEUROSURGERY, 1995, 22 (04) : 189 - 196
  • [6] Late mortality of long-term survivors of childhood cancer
    Hudson, MM
    Jones, D
    Boyett, J
    Sharp, GB
    Pui, CH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2205 - 2213
  • [7] THERAPY-RELATED LEUKEMIA AND MYELODYSPLASTIC SYNDROME - CLINICAL, CYTOGENETIC, AND PROGNOSTIC FEATURES
    KANTARJIAN, HM
    KEATING, MJ
    WALTERS, RS
    SMITH, TL
    CORK, A
    MCCREDIE, KB
    FREIREICH, EJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (12) : 1748 - 1757
  • [8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [9] CLINICAL AND CYTOGENETIC CORRELATIONS IN 63 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROMES AND ACUTE NONLYMPHOCYTIC LEUKEMIA - FURTHER EVIDENCE FOR CHARACTERISTIC ABNORMALITIES OF CHROMOSOME-5 AND CHROMOSOME-7
    LEBEAU, MM
    ALBAIN, KS
    LARSON, RA
    VARDIMAN, JW
    DAVIS, EM
    BLOUGH, RR
    GOLOMB, HM
    ROWLEY, JD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) : 325 - 345
  • [10] 2ND MALIGNANT NEOPLASMS IN CHILDREN - AN UPDATE FROM THE LATE EFFECTS STUDY-GROUP
    MEADOWS, AT
    BAUM, E
    FOSSATIBELLANI, F
    GREEN, D
    JENKIN, RDT
    MARSDEN, B
    NESBIT, M
    NEWTON, W
    OBERLIN, O
    SALLAN, SG
    SIEGEL, S
    STRONG, LC
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (04) : 532 - 538